subependymal nodular heterotopia
ORPHA: 1010302 Treatments Available
Overview
human disease
Available Treatments (2)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| Valproic Acid | Oral tablets 250mg, 500mg; Oral solution 250mg/5mL; IV infusion 100mg/mL | FDA Approved | 12 | 7d |
| Levetiracetam | Oral tablet 250mg, 500mg, 750mg, 1000mg; Oral solution 100mg/mL; IV infusion 500mg/5mL | FDA Approved, EMA Approved | 11 | 3d |
Clinical Presentation
Signs and symptoms associated with subependymal nodular heterotopia, sourced from HPO and Orphanet clinical annotations.
SeizureOccipital encephalocelePolymicrogyriaAbnormality of neuronal migrationGray matter heterotopiaFocal aware seizureAbnormal bone structureFocal-onset seizureNasofrontal encephaloceleFocal cortical dysplasiaLimb myoclonusAbnormal ethmoid bone morphologyAbnormal forehead morphologyPartial agenesis of the corpus callosumProminent glabellaVisual hallucinationMeningoceleMyelomeningoceleEEG with focal sharp slow wavesEEG with temporal focal spike wavesInterictal EEG abnormalityAcroparesthesiaAbnormality of movement
Classification & Codes
Orphanet Code
ORPHA:101030subependymal nodular heterotopia
| Orphanet | ORPHA:101030 |
| Treatments | 2 drug(s) |
| Symptoms on record | 23 signs |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO